



12/08/03

1634

EXPRESS MAIL NO. EL615430609US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kurt C. Gish, *et al.*

Application Serial No. 09/747,371

Filed: December 21, 2000

For: **METHODS FOR DETECTION AND
DIAGNOSING OF BREAST CANCER**

Art Unit: 1634

Examiner: Johannsen, Diana B.

Confirmation No.: 8631

Attorney's Docket No:
05882.00128.NPUS00

Information Disclosure Statement

MS Issue Fee

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

It is respectfully requested that the Information Disclosure Statement and the attached PTO-1449, be placed in the file.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number **05882.0128.NPUS00**.

Respectfully submitted,

Date: December 5, 2003


Albert P. Halluin (Reg. No. 25,227)
Viola T. Kung (Reg. No. 41,131)

HOWREY SIMON ARNOLD & WHITE, LLP
301 Ravenswood Avenue
Box No. 34
Menlo Park, CA 94025
Tel: (650) 463-8109
Tel. (650) 463-8181



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

05882.0128.NPUS00

APPLICATION NO.

09/747,371

APPLICANT

Kurt C. Gish, et al.

FILING DATE

December 12, 2000

GROUP

1641

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.						
	2.						
	3.						
	4.						

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	5.							
	6.							
	7.							

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, Etc.)

	8.	Amid, C., et al., "Comparative genomic sequencing reveals a strikingly similar architecture of a conserved syntenic region on human chromosome 11p15.3 (including gene ST5) and mouse chromosome 7", <i>Cytogenetics and Cell Genetics</i> , 93: 284-290 (2001)
	9.	Couto, J.R., et al., "Cloning and sequence analysis of human breast epithelial antigen BA46 reveals an RGD cell adhesion sequence presented on a neuropeptide growth factor-like domain", <i>DNA and Cell Biol.</i> , 15(4): 281-6 (1996)
	10.	Oberst, Michael D., "The Activation of Matriptase Requires Its Noncatalytic Domains, Serine Protease Domain, and Its Cognate Inhibitor", <i>J. of Biol. Chem.</i> , 278(29): 26773-9 (2003)
	11.	Yang, Ruey-Bing, "Identification of a Novel Family of Cell-surface Proteins Expressed in Human Vascular Endothelium", <i>J. of Biol. Chem.</i> , 277(48): 46364-73 (2002)
	12.	
	13.	
	14.	
	15.	
	16.	
	17.	
	18.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.